Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgia

Abstract

BackgroundPost-herpetic neuralgia (PHN) is the most common and most debilitating complication of herpes zoster, and involves considerable associated costs.ObjectiveThis paper presents results from nine health economic studies undertaken in eight European countries that compared lidocaine medicated plaster with gabapentin and/or pregabalin in PHN. It aims to support the increasing need for published cost-effectiveness data for health care decision-making processes in Europe.MethodsAll studies were based on a similar core Markov model with data derived from clinical trials, local Delphi panels, and official national price and tariff lists. The main outcome measure was cost per quality-adjusted life year gained; time without pain or intolerable adverse events was also included as a secondary outcome measure. All studies focused on an elderly population of patients with PHN who had insufficient pain relief with standard analgesics and could not tolerate or had contraindications to tricyclic antidepressants.ResultsDespite considerable differences in many of the variables used, the results showed remarkable similarity and suggested that use of lidocaine medicated plaster offered cost-savings in many of the countries studied, where it proved a highly cost-effective alternative to both gabapentin and pregabalin.ConclusionLidocaine medicated plaster is a cost-effective alternative to gabapentin and pregabalin in the treatment of PHN. These savings are largely the result of the superior safety profile of the lidocaine medicated plaster.

Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China

“…Markov model is widely used in disease models with multistate transition. In this study, the Markov state transition model was established based on the treatment plan of PHN disease according to the methods of Liedgens et al (7) (Figure 1). The time horizon of the model was 6 months, the cycle was 1 month, and the model had 5 states.…”

“…The data on transition probabilities between states in each treatment group were derived from a 2013 European study (7), from which the state transition probability data of a head-to-head study in the UK (8) were selected (Table 1). Due to the limited clinical data on domestic LMPs, there was insufficient information to obtain all the transition probabilities in this model.…”

“…The control group was analyzed with reference to the scenario analysis in the European Health Economics study (7).…”

“…In the scenario analysis of the European Health Economics study (7), the United Kingdom, Spain, Austria, and Portugal all cited 1.1 unit of LMP in comparison to 488 mg PG, as 1.1 unit of LMP was considered to be a frequently used dose in the clinical setting. According to the input model, the total cost of 1.1 unit of LMP during the 6-month treatment period was 5,686.3 CNY, and the average cost-effectiveness ratio was 13,366.0 CNY/QALY.…”

Aplicação do adesivo de lidocaína 5% em cicatrizes cirúrgicas dolorosas: Ensaio clínico

“…Lidocaine patches are considered a first-line medication in patients with neuropathic pain or post-herpetic neuralgia (PHN), and it was superior to pregabalin in these subjects. 3 4 5 …”